Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New Data Demonstrates Victoza® (liraglutide rDNA injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52…

June 26, 2010 By Bio-Medicine.Org

ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ — Poster
16LB — Late-breaking Novo Nordisk (NVO) extension data presented
today at the 70th Annual Scientific Sessions of the American
Diabetes Association (ADA) showed that once-daily Victoza® in
combination with metformin produced sustained and significantly
greater reductions in A1c, body weight and fasting plasma glucose
(FPG) than Januvia® plus metformin at 52 weeks.

Key findings from the study include:

  • Patients treated with 1.2 mg and 1.8 mg of Victoza®
    experienced greater reductions in A1c than those treated with
    Januvia® 100 mg (-1.3% and -1.5% versus -0.9%)
  • Victoza® provided greater weight loss versus patients
    treated with Januvia® (2.8 kg [6.16 lbs] and 3.7 kg [8.14 lbs] for 1.2 mg and 1.8 mg respectively, 1.2 kg [2.64 lbs] for
    Januvia®)
  • Victoza® provided greater change from baseline FPG readings
    than those treated with Januvia® (-1.7 mmol/L and -2.0 mmol/L
    for 1.2 mg and 1.8 mg respectively, versus -0.6 mmol/L)
  • Patients treated with Victoza® 1.8 mg reported
    significantly greater treatment satisfaction than those treated
    with Januvia®

“What is so encouraging about these data is that Victoza® at
both doses was more effective than Januvia® at achieving blood
sugar control in people with type 2 diabetes over a period of one
year.  Patients who began the trial with higher A1c levels
achieved greater reductions in A1c with treatment with
Victoza®,” said Dr. Richard
Pratley
, of the Diabetes and Metabolism Translational
Medicine Unit, University of Vermont
College of Medicine, Burlington.
 “Altho

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech